DNLI DENALI THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, DENALI THERAPEUTICS INC reported revenue of $3.60M, net income of −$128M and diluted EPS of −$0.68; for the fiscal year ended December 2025 revenue was $0.

DNLI annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$555M, net income −$513M (margin n/a), EPS −$2.97
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$487M, net income −$423M (margin n/a), EPS −$2.57
• Fiscal year ended Dec 2023: revenue $331M, gross profit n/a, operating income −$197M, net income −$145M (margin -43.9%), EPS −$1.06
• Fiscal year ended Dec 2022: revenue $108M, gross profit n/a, operating income −$341M, net income −$326M (margin -300.6%), EPS −$2.60
• Fiscal year ended Dec 2021: revenue $48.7M, gross profit n/a, operating income −$296M, net income −$291M (margin -597.2%), EPS −$2.39

DNLI quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $3.60M, net income −$128M, EPS −$0.68
• Quarter ended Mar 31, 2026: revenue n/a, net income −$128M, EPS −$0.69
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$129M, EPS −$0.73
• Quarter ended Sep 30, 2025: revenue n/a, net income −$127M, EPS −$0.74
• Quarter ended Jun 30, 2025: revenue $0, net income −$124M, EPS −$0.72
• Quarter ended Mar 31, 2025: revenue n/a, net income −$133M, EPS −$0.78
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$115M, EPS −$0.67
• Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$107M, EPS −$0.63
• Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$99.0M, EPS −$0.59
• Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$102M, EPS −$0.68
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0 (down 100.0% year over year), net income −$119M, EPS −$0.84
• Quarter ended Sep 30, 2023: revenue $1.27M (down 64.4% year over year), net income −$99.4M, EPS −$0.72
• Quarter ended Jun 30, 2023: revenue $294M (up 460.4% year over year), net income $183M, EPS $1.30
• Quarter ended Mar 31, 2023: revenue $35.1M (down 16.6% year over year), net income −$110M, EPS −$0.80
• Quarter ended Dec 31, 2022 (from the annual report): revenue $10.3M (down 17.8% year over year), net income −$98.7M, EPS −$0.75
• Quarter ended Sep 30, 2022: revenue $3.56M (down 32.7% year over year), net income −$103M, EPS −$0.84
• Quarter ended Jun 30, 2022: revenue $52.5M (up 128.8% year over year), net income −$58.8M, EPS −$0.48
• Quarter ended Mar 31, 2022: revenue $42.1M (up 431.9% year over year), net income −$65.2M, EPS −$0.53
• Quarter ended Dec 31, 2021 (from the annual report): revenue $12.5M, net income −$75.3M, EPS −$0.62
• Quarter ended Sep 30, 2021: revenue $5.29M, net income −$84.6M, EPS −$0.69

DNLI cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$413M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$348M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$358M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$245M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$211M, share buybacks n/a

DNLI balance sheet

• Jun 30, 2026: cash $202M, total assets $1.16B, total liabilities $323M, shareholders' equity $835M
• Mar 31, 2026: cash $388M, total assets $1.27B, total liabilities $340M, shareholders' equity $926M
• Dec 31, 2025: cash $205M, total assets $1.14B, total liabilities $131M, shareholders' equity $1.01B
• Sep 30, 2025: cash $91.0M, total assets $1.06B, total liabilities $129M, shareholders' equity $926M
• Jun 30, 2025: cash $141M, total assets $1.17B, total liabilities $139M, shareholders' equity $1.03B
• Mar 31, 2025: cash $56.9M, total assets $1.27B, total liabilities $149M, shareholders' equity $1.12B
• Dec 31, 2024: cash $175M, total assets $1.37B, total liabilities $144M, shareholders' equity $1.23B
• Sep 30, 2024: cash $90.6M, total assets $1.45B, total liabilities $136M, shareholders' equity $1.32B

What is DNLI's revenue?

DENALI THERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.

Is DNLI profitable?

No. DENALI THERAPEUTICS INC lost $511M over the last four quarters.

What is DNLI's EPS?

Diluted earnings per share over the last four quarters were −$2.84; −$0.68 in the latest quarter.

DNLI ownership and insider trades · All stocks